Codexis, Inc. (NASDAQ:CDXS) is one of the 10 Best High-Risk Penny Stocks to Buy Right Now. On March 12, Matt Hewitt of Craig-Hallum reiterated his Buy rating on Codexis, Inc. (NASDAQ:CDXS). Just a day prior to this, TD Cowen analyst Brendan Smith also maintained his Hold rating on the stock with a price target of $2. This is the lowest price target for the shares on Wall Street, and it still offers 36% upside from here. Codexis Inc (NASDAQ:CDXS) announced its Q4 2025 earnings on March 11, reporting $38.9 ...

Earnings Call InsightsCodexis outlines $72M–$76M 2026 revenue target as ECO Synthesis gains momentum and CDMO partnerships expandMar. 11, 2026 7:52 PM ETCodexis, Inc. (CDXS) StockAI-Generated Earnings Calls InsightsCommentsEarnings Call Insights: Codexis (CDXS) Q4 2025 Management View CEO Alison Moore stated that Codexis is now focused on RNA medicine and has developed the ECO Synthesis manufacturing platform to address challenges in current siRNA production technology. Moore highlighted, "We reached anNews ...

Financial Data and Key Metrics Changes - Total revenues for Q4 2025 were $38.9 million, up from $21.5 million in Q4 2024, primarily due to a technology transfer agreement with Merck [21] - For the full year 2025, revenue was $70.4 million compared to $59.3 million in 2024 [21] - Product gross margin for Q4 2025 was 64%, consistent with the full year 2025 gross margin, which also stood at 64%, up from 56% in the prior year [22] - Net income for Q4 2025 was $9.6 million, compared to a net loss of $10.4 million in Q4 2024; net loss for the full year 2025 was $44 million, improved from a loss of $65.3 million in 2024 [24][25] Business Line Data and Key Metrics Changes - The small molecule biocatalysis business returned to a healthy profit margin, with stabilization in revenue, supported by a robust pipeline of drugs in late-stage clinical studies [10] - The ECO Synthesis platform achieved significant milestones, including synthesizing 10 grams of commercially relevant siRNA and scaling production to 100 grams, with plans to reach half a kilo by the end of 2026 [6][7] Market Data and Key Metrics Changes - The total addressable annual market for production technologies in five years is estimated to be $2 billion, with a growing demand for siRNA medicines at a rate of 5%-10% per year [5] - The industry is projected to require 10-30 metric tons of oligonucleotide material by 2030, indicating a significant addressable market for the company [57] Company Strategy and Development Direction - The company is focused on establishing itself as a key technology provider in the RNA medicine market through its ECO Synthesis platform, which aims to address challenges in siRNA production [4][5] - Plans include scaling up production capabilities, achieving GMP certification, and expanding partnerships with CDMOs to enhance manufacturing processes [8][10] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the growth potential of the ECO Synthesis platform and the overall siRNA market, highlighting the importance of innovation and customer collaboration [12][28] - The company aims to demonstrate proof of success through new contracts and licensing deals in 2026, while maintaining a focus on financial performance and expense management [27][29] Other Important Information - The company ended 2025 with $78.2 million in cash equivalents, expected to fund operations and capital expenditures through the end of 2027 [25] - A restructuring charge of $3.4 million was recorded in Q4 2025 as part of efforts to reduce operating costs and improve gross margins [24] Q&A Session Summary Question: Potential value of stereoisomer control - Management is actively exploring the biological activity of stereo configurations and plans to present data at the TIDES USA meeting, with several customers interested in collaboration [31][32] Question: Understanding the recent deal process - The recent deal involved a small organization with a cardiovascular asset, highlighting the long-term discussions and mutual excitement about the ECO Synthesis platform's capabilities [35][39] Question: Details on the 50-gram contract - The initial agreement is for preclinical work, with expectations that successful data will lead to IND submissions and larger contracts for clinical trials [41][43] Question: Revenue guidance visibility - Management indicated a significant portion of the $72 million-$76 million revenue guidance is based on historical buying practices, though some estimates remain speculative at the beginning of the year [50][51] Question: Growth expectations for biocatalysis business - The small molecule biocatalysis business is expected to stabilize and continue to fuel growth, while higher growth rates are anticipated from the ECO side of the business [62][65]

Financial Data and Key Metrics Changes - Total revenues for Q4 2025 were $38.9 million, up from $21.5 million in Q4 2024, primarily due to a technology transfer agreement with Merck [20] - For the full year 2025, revenue was $70.4 million compared to $59.3 million in 2024 [20] - Product gross margin for Q4 2025 was 64%, consistent with the full year 2025 gross margin, which also stood at 64%, an increase from 56% in the prior year [20][21] - Net income for Q4 2025 was $9.6 million, compared to a loss of $10.4 million in Q4 2024, while the net loss for the full year 2025 was $44 million, down from $65.3 million in 2024 [24][25] Business Line Data and Key Metrics Changes - The small molecule biocatalysis business returned to a healthy profit margin in 2025, with stabilization in revenue expected to fuel growth for the next 3-5 years [9] - The ECO Synthesis platform achieved significant milestones, including synthesizing 10 grams of commercially relevant siRNA and scaling up production to 100 grams, with plans to reach half a kilo by the end of 2026 [5][6] Market Data and Key Metrics Changes - The total addressable annual market for production technologies in RNA medicine is estimated to be $2 billion in five years, with a growing demand for siRNA medicines at a rate of 5%-10% per year [4][5] - The industry is projected to require 10-30 metric tons of oligonucleotide material by 2030, indicating a significant addressable market for the company [55] Company Strategy and Development Direction - The company aims to establish itself as a key technology provider in the RNA medicine market, focusing on the ECO Synthesis platform to address production challenges [4][5] - Plans for 2026 include scaling up the ECO Synthesis manufacturing platform, achieving half-kilogram scale, and beginning construction of a GMP facility to support customer needs [7][28] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the demand for siRNA therapeutics and the company's ability to meet this demand through innovative technology [55] - The company anticipates that 2026 will be a year of significant progress, with a revenue target of $72 million to $76 million, and expects to maintain stable gross margins [25][27] Other Important Information - The company ended 2025 with $78.2 million in cash equivalents, expected to fund operations and capital expenditures through the end of 2027 [25] - A restructuring charge of $3.4 million was recorded in Q4 2025 as part of efforts to reduce operating costs and improve gross margins [24] Q&A Session Summary Question: Potential value for stereoisomer control - Management is actively exploring the biological activity of stereo configurations generated by the ECO Synthesis platform and plans to present data at the TIDES USA meeting [31][32] Question: Understanding the recent announced deal - The recent deal involves a small organization with a cardiovascular asset, and discussions have been ongoing for many months to address their manufacturing challenges [35][39] Question: Details on the 50-gram contract - The initial agreement is for preclinical work, and if successful, the company will progress to IND submissions and potentially commercial agreements for larger quantities [41][43] Question: Revenue guidance visibility - Management indicated that a significant portion of the $72 million-$76 million revenue guidance is based on historical buying practices, with some speculative elements due to the early part of the year [49][50] Question: Industry demand for siRNA - Management noted that the siRNA therapeutic pipeline is vibrant, with a growing number of assets in clinical trials, projecting a significant increase in demand by 2030 [53][55] Question: Revenue mix and growth expectations - The company expects growth to primarily come from the ECO side of the business, while the small molecule biocatalysis business is expected to stabilize and contribute to growth over the next few years [60][63]

Summary of Codexis Conference Call Company Overview - **Company**: Codexis - **Industry**: Biotechnology, specifically focusing on RNA medicines and biocatalytic enzymes Key Points and Arguments 1. **Evolution of Codexis**: Codexis has evolved to focus on RNA medicines, developing innovative manufacturing technologies over the past 3-4 years, particularly through its proprietary biocatalytic enzymes [4][6] 2. **Growth Opportunities**: Significant contracts are expected from existing customers utilizing the ECO Synthesis manufacturing platform, which may lead to improved potency of generated assets [6] 3. **Market Growth**: The RNA medicines market, particularly siRNA medicines, is projected to grow at a rate of 5% to 10% annually, with a total addressable market (TAM) expected to reach $2 billion by 2030 [8][10] 4. **Production Limitations**: Current production technologies for oligonucleotides are limited in scale, with traditional methods only able to produce 5 to 10 kilos at most, creating a substantial opportunity for Codexis's innovative solutions [9][10] 5. **Strategic Shift**: Codexis is deprioritizing its legacy small molecule biocatalysis business due to increased competition and commoditization, focusing instead on high-potential RNA therapeutics [12] 6. **Supply Agreement with Merck**: A unique $38 million supply assurance agreement with Merck was established to mitigate supply chain risks, indicating the critical nature of Codexis's enzymes in Merck's operations [15] 7. **CDMO Partnerships**: Codexis has three agreements with Contract Development and Manufacturing Organizations (CDMOs), which are crucial for scaling production and addressing current production limitations [18][20] 8. **TIDES Conference**: Codexis has utilized the TIDES conference to showcase the scalability and operational simplicity of its ECO Synthesis platform, generating significant interest from potential customers [22][24] 9. **Revenue Generation**: Codexis is currently engaged in feasibility projects with customers, aiming to transition these into more substantial licensing agreements in the near future [26] 10. **Expansion Strategy**: The company aims to prioritize existing clients for expansion while also exploring new revenue-generating contracts, with over 50 active conversations in the sales funnel [27][29] 11. **Scalability Goals**: Codexis is currently operating at a 100-gram scale, with plans to progress to kilo scale by the end of the year, supported by a new manufacturing facility expected to be operational by the end of 2027 [31][32] 12. **Investment Plans**: The company plans to invest between $20 million and $25 million in capital improvements for its new facility, which will support kilo scale production [35] 13. **Therapeutic Landscape**: Codexis is closely monitoring the development of siRNA assets, with a focus on larger patient populations and advancements in targeting technologies that could enhance the efficacy of RNA therapies [38][40] 14. **Competitive Positioning**: Codexis believes it holds a competitive advantage in enzymatic synthesis and aims to leverage its proprietary technology to attract customers facing production challenges [42] Additional Important Content - Codexis is actively engaged in discussions with both large biopharmaceutical companies and startups, indicating a diverse customer base that can validate its technology [29] - The company is focused on delivering high product quality and scalable manufacturing processes to meet the needs of its clients in the evolving genomic medicine landscape [28][40]

Core Insights - Codexis Inc. has achieved ISO 9001:2015 certification, demonstrating its commitment to high-quality manufacturing processes across all operations [1][4]. Group 1: Certification Details - The ISO 9001:2015 certification reflects Codexis's dedication to quality assurance in research and development, product manufacturing, testing, delivery, support, and customer service [1][2]. - The certification applies to Codexis's headquarters in Redwood City, California, which includes research and development facilities and a non-GMP manufacturing facility [2]. Group 2: Quality Management System - ISO 9001 is a globally recognized standard for establishing and certifying a quality management system (QMS), applicable to organizations of all types and sizes [3]. - The certification signifies that Codexis has implemented effective processes and controls to ensure consistent quality from design to delivery [4]. Group 3: Company Overview - Codexis is a leading provider of enzymatic solutions for scalable therapeutics manufacturing, utilizing its proprietary CodeEvolver technology platform [5]. - The company is developing the ECO Synthesis manufacturing platform to enable the scaled manufacture of RNAi therapeutics through an enzymatic route, aiming for higher yields and reduced energy usage [5].

Core Insights - Codexis, Inc. has signed a lease for a 34,000 square foot GMP manufacturing facility in Hayward, California, marking a significant step in its transformation into a key development partner for enzymatic manufacturing of oligonucleotides [1][3] Company Developments - The new facility will enhance Codexis's internal capabilities for GMP manufacturing of siRNA and other oligonucleotides using its ECO Synthesis platform, with modifications expected to begin in early 2026 [2] - The facility's flexible design will also support the scaling of high-quality purified enzymes, which are essential components of the ECO Synthesis platform [2] Strategic Vision - The establishment of this facility is seen as a pivotal move for Codexis, allowing the company to provide manufacturing services to customers for early clinical trials, thereby reinforcing its commitment to improving siRNA production quality and service [3] - The adaptability of the facility is intended to meet the evolving needs of the business, positioning Codexis as a full-service manufacturing technology innovator in the oligonucleotide sector [3][4]